AtriCure price target raised to $58 from $55 at Needham

Needham analyst Mike Matson raised the firm’s price target on AtriCure to $58 from $55 and keeps a Buy rating on the shares. The analyst named AtriCure his top pick for 2023 and added shares to the firm’s Conviction List. AtriCure has three significant growth drivers that have potential to drive upside to consensus in 2023: the EnCompass Clamp, cryoSPHERE probe, and AtriClip, Matson tells investors in a research note, adding that he expects AtriCure to see EBITDA margin improvement and to reach positive adjusted EBITDA in 2023.